Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism TNFR2 modulators(Tumor necrosis factor receptor superfamily member 1B modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 1 | CN | 15 Aug 2023 | |
Advanced cancer | Phase 1 | CN | 14 Aug 2023 | |
Solid tumor | Phase 1 | US | 23 Dec 2022 | |
Hematologic Neoplasms | Phase 1 | - | - | |
Breast Cancer | IND Approval | CN | 13 Feb 2023 | |
Colonic Cancer | IND Approval | CN | 13 Feb 2023 | |
Cutaneous T-Cell Lymphoma | IND Approval | CN | 13 Feb 2023 | |
Lung Cancer | IND Approval | CN | 13 Feb 2023 | |
Ovarian Cancer | IND Approval | CN | 13 Feb 2023 |